Risk of chemotherapy-induced peripheral neuropathy in large population-based cohorts of elderly patients with breast, ovarian, and lung cancer

Zhannat Nurgalieva, Rui Xia, Chih Chin Liu, Keith Burau, Dale Sharon Hardy, Xianglin L. Du

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

There is little information on chemotherapy-induced peripheral neuropathy (PN) for community-dwelling patients with cancer. We studied 65,316 patients with breast cancer, 9242 with ovarian cancer, and 86,278 with non-small cell lung cancer from 1991 through 2002 identified from the 16 areas of Surveillance, Epidemiology and End Results. The incidence density of PN was 15.3, 21.5, and 18.3 per 1000 person-years for patients with breast, ovarian, and lung cancer who received platinum-taxane combination chemotherapy, respectively. Patients with breast, ovarian, and lung cancer receiving taxanes were more than twice as likely to develop PN compared with those not receiving chemotherapy (adjusted hazard ratio = 2.22, 95% confidence interval = 1.85-2.66 in patients with breast cancer), whereas patients who received platinum-taxane combination chemotherapy were more than 3 times as likely to develop PN compared with women who did not receive chemotherapy (adjusted hazard ratio = 3.33, 95% confidence interval = 2.05-5.05). In patients with ovarian or lung cancer receiving taxanes or platinum-taxane combination therapy, the risk of PN was increased with increasing number of chemotherapy cycles. These findings remained similar after adjusting for the history of preexisting PN or diabetes. Close monitoring for PN in patients receiving taxanes alone or in combination with platinum compounds may be warranted.

Original languageEnglish (US)
Pages (from-to)148-158
Number of pages11
JournalAmerican journal of therapeutics
Volume17
Issue number2
DOIs
StatePublished - Mar 1 2010

Fingerprint

Peripheral Nervous System Diseases
Ovarian Neoplasms
Lung Neoplasms
Breast Neoplasms
Drug Therapy
Taxoids
Population
Platinum
Combination Drug Therapy
Confidence Intervals
Platinum Compounds
Independent Living
Non-Small Cell Lung Carcinoma
Epidemiology
History
Incidence
taxane

Keywords

  • Breast cancer
  • Chemotherapy
  • Lung cancer
  • Ovarian cancer
  • Peripheral neuropathy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Risk of chemotherapy-induced peripheral neuropathy in large population-based cohorts of elderly patients with breast, ovarian, and lung cancer. / Nurgalieva, Zhannat; Xia, Rui; Liu, Chih Chin; Burau, Keith; Hardy, Dale Sharon; Du, Xianglin L.

In: American journal of therapeutics, Vol. 17, No. 2, 01.03.2010, p. 148-158.

Research output: Contribution to journalArticle

Nurgalieva, Zhannat ; Xia, Rui ; Liu, Chih Chin ; Burau, Keith ; Hardy, Dale Sharon ; Du, Xianglin L. / Risk of chemotherapy-induced peripheral neuropathy in large population-based cohorts of elderly patients with breast, ovarian, and lung cancer. In: American journal of therapeutics. 2010 ; Vol. 17, No. 2. pp. 148-158.
@article{c6671c3163bb42348c6ae50ae93e3e04,
title = "Risk of chemotherapy-induced peripheral neuropathy in large population-based cohorts of elderly patients with breast, ovarian, and lung cancer",
abstract = "There is little information on chemotherapy-induced peripheral neuropathy (PN) for community-dwelling patients with cancer. We studied 65,316 patients with breast cancer, 9242 with ovarian cancer, and 86,278 with non-small cell lung cancer from 1991 through 2002 identified from the 16 areas of Surveillance, Epidemiology and End Results. The incidence density of PN was 15.3, 21.5, and 18.3 per 1000 person-years for patients with breast, ovarian, and lung cancer who received platinum-taxane combination chemotherapy, respectively. Patients with breast, ovarian, and lung cancer receiving taxanes were more than twice as likely to develop PN compared with those not receiving chemotherapy (adjusted hazard ratio = 2.22, 95{\%} confidence interval = 1.85-2.66 in patients with breast cancer), whereas patients who received platinum-taxane combination chemotherapy were more than 3 times as likely to develop PN compared with women who did not receive chemotherapy (adjusted hazard ratio = 3.33, 95{\%} confidence interval = 2.05-5.05). In patients with ovarian or lung cancer receiving taxanes or platinum-taxane combination therapy, the risk of PN was increased with increasing number of chemotherapy cycles. These findings remained similar after adjusting for the history of preexisting PN or diabetes. Close monitoring for PN in patients receiving taxanes alone or in combination with platinum compounds may be warranted.",
keywords = "Breast cancer, Chemotherapy, Lung cancer, Ovarian cancer, Peripheral neuropathy",
author = "Zhannat Nurgalieva and Rui Xia and Liu, {Chih Chin} and Keith Burau and Hardy, {Dale Sharon} and Du, {Xianglin L.}",
year = "2010",
month = "3",
day = "1",
doi = "10.1097/MJT.0b013e3181a3e50b",
language = "English (US)",
volume = "17",
pages = "148--158",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Risk of chemotherapy-induced peripheral neuropathy in large population-based cohorts of elderly patients with breast, ovarian, and lung cancer

AU - Nurgalieva, Zhannat

AU - Xia, Rui

AU - Liu, Chih Chin

AU - Burau, Keith

AU - Hardy, Dale Sharon

AU - Du, Xianglin L.

PY - 2010/3/1

Y1 - 2010/3/1

N2 - There is little information on chemotherapy-induced peripheral neuropathy (PN) for community-dwelling patients with cancer. We studied 65,316 patients with breast cancer, 9242 with ovarian cancer, and 86,278 with non-small cell lung cancer from 1991 through 2002 identified from the 16 areas of Surveillance, Epidemiology and End Results. The incidence density of PN was 15.3, 21.5, and 18.3 per 1000 person-years for patients with breast, ovarian, and lung cancer who received platinum-taxane combination chemotherapy, respectively. Patients with breast, ovarian, and lung cancer receiving taxanes were more than twice as likely to develop PN compared with those not receiving chemotherapy (adjusted hazard ratio = 2.22, 95% confidence interval = 1.85-2.66 in patients with breast cancer), whereas patients who received platinum-taxane combination chemotherapy were more than 3 times as likely to develop PN compared with women who did not receive chemotherapy (adjusted hazard ratio = 3.33, 95% confidence interval = 2.05-5.05). In patients with ovarian or lung cancer receiving taxanes or platinum-taxane combination therapy, the risk of PN was increased with increasing number of chemotherapy cycles. These findings remained similar after adjusting for the history of preexisting PN or diabetes. Close monitoring for PN in patients receiving taxanes alone or in combination with platinum compounds may be warranted.

AB - There is little information on chemotherapy-induced peripheral neuropathy (PN) for community-dwelling patients with cancer. We studied 65,316 patients with breast cancer, 9242 with ovarian cancer, and 86,278 with non-small cell lung cancer from 1991 through 2002 identified from the 16 areas of Surveillance, Epidemiology and End Results. The incidence density of PN was 15.3, 21.5, and 18.3 per 1000 person-years for patients with breast, ovarian, and lung cancer who received platinum-taxane combination chemotherapy, respectively. Patients with breast, ovarian, and lung cancer receiving taxanes were more than twice as likely to develop PN compared with those not receiving chemotherapy (adjusted hazard ratio = 2.22, 95% confidence interval = 1.85-2.66 in patients with breast cancer), whereas patients who received platinum-taxane combination chemotherapy were more than 3 times as likely to develop PN compared with women who did not receive chemotherapy (adjusted hazard ratio = 3.33, 95% confidence interval = 2.05-5.05). In patients with ovarian or lung cancer receiving taxanes or platinum-taxane combination therapy, the risk of PN was increased with increasing number of chemotherapy cycles. These findings remained similar after adjusting for the history of preexisting PN or diabetes. Close monitoring for PN in patients receiving taxanes alone or in combination with platinum compounds may be warranted.

KW - Breast cancer

KW - Chemotherapy

KW - Lung cancer

KW - Ovarian cancer

KW - Peripheral neuropathy

UR - http://www.scopus.com/inward/record.url?scp=77949975990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949975990&partnerID=8YFLogxK

U2 - 10.1097/MJT.0b013e3181a3e50b

DO - 10.1097/MJT.0b013e3181a3e50b

M3 - Article

VL - 17

SP - 148

EP - 158

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 2

ER -